Cheraghlou et al1 reviewed data from the National Cancer Database (NCDB) to evaluate whether overall survival differs when patients with T1a-T2a melanomas are treated with Mohs micrographic surgery (MMS) in high- vs low-volume or academic vs nonacademic facilities. Analysis was limited to this population based on previous work, which reported improved overall survival among patients with T1a-T2a melanoma treated with MMS compared with wide local excision (WLE).2 The authors present 10 years of retrospective NCDB data on 4062 T1a-T2a melanomas treated with MMS and report that patients were nearly 30% less likely to die when MMS was performed at academic vs nonacademic facilities (hazard ratio [HR], 0.730; 95% CI, 0.596-0.895; P = .002) and 20% less likely to die when MMS was performed at high- vs low-volume facilities (HR, 0.795; 95% CI, 0.648-0.977; P = .03).